Correlation Between Molecular Partners and Aerovate Therapeutics

Can any of the company-specific risk be diversified away by investing in both Molecular Partners and Aerovate Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and Aerovate Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Molecular Partners AG and Aerovate Therapeutics, you can compare the effects of market volatilities on Molecular Partners and Aerovate Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of Aerovate Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and Aerovate Therapeutics.

Diversification Opportunities for Molecular Partners and Aerovate Therapeutics

0.36

Correlation Coefficient

Molecular Partners  Aerovate Therapeutics

Weak diversification

The 3 months correlation between Molecular and Aerovate is 0.36. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and Aerovate Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aerovate Therapeutics and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with Aerovate Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aerovate Therapeutics has no effect on the direction of Molecular Partners i.e., Molecular Partners and Aerovate Therapeutics go up and down completely randomly.

Pair Corralation between Molecular Partners and Aerovate Therapeutics

Given the investment horizon of 90 days Molecular Partners AG is expected to under-perform the Aerovate Therapeutics. In addition to that, Molecular Partners is 1.79 times more volatile than Aerovate Therapeutics. It trades about -0.07 of its total potential returns per unit of risk. Aerovate Therapeutics is currently generating about -0.07 per unit of volatility. If you would invest  263.00  in Aerovate Therapeutics on November 29, 2024 and sell it today you would lose (22.00) from holding Aerovate Therapeutics or give up 8.37% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Molecular Partners AG  vs.  Aerovate Therapeutics

Molecular Partners

Risk-Adjusted Performance

Very Weak

Over the last 90 days Molecular Partners AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Aerovate Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Aerovate Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest fragile performance, the Stock's basic indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Pair Trading with Molecular Partners and Aerovate Therapeutics

The main advantage of trading using opposite Molecular Partners and Aerovate Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, Aerovate Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aerovate Therapeutics will offset losses from the drop in Aerovate Therapeutics' long position.

The idea behind Molecular Partners AG and Aerovate Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.